Niramai vs Paige AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. Niramai employs 50-200 people, while Paige AI has 100-500 employees.

Paige AI has raised more in total funding at $125M, compared to Niramai's $17M — a gap of $108M.

Paige AI holds the higher Awaira Score at 65/100, compared to Niramai's 60/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 5-point gap that reflects meaningful differences in scale or traction.

Niramai was founded by Geetha Manjunath in 2016. Paige AI was founded by Leo Grady in 2018. Visit each company's profile on Awaira for a full founder biography.

Niramai: Niramai has developed a radiation-free, non-contact breast cancer screening solution that uses thermal imaging combined with AI-powered image analysis to detect early-stage breast cancer, addressing the significant access and cost barriers that prevent widespread mammography screening in low- and middle-income countries. The technology works without X-ray radiation, requires no radiologist for initial interpretation, and can be deployed in mobile screening units.\n\nThe company raised approximately $17M in Series B funding and has conducted clinical validation studies demonstrating sensitivity and specificity metrics competitive with mammography for early detection. Niramai has deployed its screening solution at hospitals, corporate wellness programs, and rural health camps across India.\n\nBreast cancer is the most common cancer among Indian women, yet screening rates remain critically low due to equipment costs, specialist shortages, and cultural barriers to mammography. Niramai's AI-powered thermal screening addresses each of these barriers simultaneously, positioning the company at the intersection of AI healthcare innovation and a major Indian public health challenge. Paige AI: Paige AI develops AI-powered pathology software that assists pathologists in identifying cancer and other diseases in digital whole-slide images. The platform received the first-ever FDA authorization for an AI-based primary diagnostic tool in pathology, a milestone that establishes regulatory precedent for clinical AI deployment in histopathology workflows.\n\nThe company raised approximately 125 million USD and partners with major academic medical centers and pathology laboratories to integrate its diagnostic AI into clinical workflows. Paige has expanded beyond prostate cancer detection into additional cancer types and is building a multi-cancer detection platform intended to function as a comprehensive AI layer across pathology departments.\n\nDigital pathology combined with AI represents one of the clearest near-term commercialization opportunities in medical AI, as the transition from glass slides to whole-slide imaging creates a digital substrate that AI can operate on at scale. Paige FDA clearance creates a significant regulatory moat that competitors must match before selling comparable diagnostic tools in the US market, giving the company a durable first-mover advantage in the AI-augmented pathology workflow.

Niramai was founded first in 2016, giving it 2 years of additional market experience. Paige AI was founded later in 2018. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

Niramai has approximately 50-200 employees, while Paige AI has approximately 100-500. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, Niramai and Paige AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.